公开(公告)号：US11266733B2

公开(公告)日：2022-03-08

申请号：US16650790

申请日：2018-09-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Wivine Burny ,  Cindy Castado ,  Sandra Giannini ,  Julien Thierry Massaux

IPC: C12N15/86 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K39/385

Abstract: Nucleotide constructs encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, immunogenic compositions comprising such constructs and a pharmaceutically acceptable carrier, and uses thereof.

公开(公告)号：US10745449B2

公开(公告)日：2020-08-18

申请号：US16023164

申请日：2018-06-29

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand Blais ,  Cindy Castado ,  Patrick Chomez ,  Marianne Dewerchin

IPC: A61K39/00 ,  A61K39/02 ,  A61K47/00 ,  C07K14/21 ,  A61K39/102 ,  A61K39/104 ,  C07K16/12

Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

公开(公告)号：US10040832B2

公开(公告)日：2018-08-07

申请号：US15119220

申请日：2015-02-20

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand Blais ,  Cindy Castado ,  Patrick Chomez ,  Marianne Dewerchin

IPC: A61K39/00 ,  C07K14/21 ,  C07K16/12 ,  A61K39/102 ,  A61K39/104

Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

公开(公告)号：US20180354996A1

公开(公告)日：2018-12-13

申请号：US16023164

申请日：2018-06-29

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand Blais ,  Cindy Castado ,  Patrick Chomez ,  Marianne Dewerchin

IPC: C07K14/21 ,  A61K39/104 ,  A61K39/102 ,  C07K16/12 ,  A61K39/00

Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

公开(公告)号：US10947280B2

公开(公告)日：2021-03-16

申请号：US16914750

申请日：2020-06-29

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand Blais ,  Cindy Castado ,  Patrick Chomez ,  Marianne Dewerchin

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/102 ,  C07K14/21 ,  A61K39/104 ,  C07K16/12

Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.